Big Pharma throws out old models in the race to a Covid-19 vaccine
From research collaborations to changes to drug development, pharma will have to find new ways of working to discover Covid-19 treatments.
Covid-19 oils the wheels of business development
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.
The scramble to reinvent the ventilator
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
Astrazeneca throws Silence an $80m lifeline
Silence has received an important validation, but making progress could be tough.
Bispecifics keep the business development fires burning
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
After Takeda endorsement Curadev’s Sting attracts Bayer
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
Becton Dickinson out for blood with new partnership
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
Collaborative diabetes tech on the Horizon
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
Cash-rich biotechs turn down the licensing deal volume
Last year saw a dip in licensing deals across biopharma, though up-front payments held up and in some areas jumped considerably.
